Last reviewed · How we verify

NCT02861963

Choice of Palliative Procedures for Pulmonary Atresia With Ventricular Septal Defect Patients

Completed NA Last updated 30 June 2020
What this trial tests

NA trial testing Experimental: RVOT reconstruction by femoral allogenic vein valve conduit in Pulmonary Atresia With Ventricular Septal Defect in 24 participants. Completed in 22 November 2019.

Timeline
5 May 2016
Primary endpoint
18 March 2019
22 November 2019

Quick facts

Lead sponsorMeshalkin Research Institute of Pathology of Circulation
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment24
Start date5 May 2016
Primary completion18 March 2019
Estimated completion22 November 2019
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Meshalkin Research Institute of Pathology of Circulation

Who can join

Adults 1 Day to 1, any sex, with Pulmonary Atresia With Ventricular Septal Defect or Tetralogy of Fallot With Pulmonary Atresia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim is to compare effective growth true hypoplastic pulmonary arteries using Right Ventricle Outflow Tract Reconstruction by femoral allogenic vein valve conduit and systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The molecular mechanisms of cardiac development and related diseases.
    Li Y, Du J, Deng S, Liu B, et al · · 2024 · cited 53× · PMID 39715759 · DOI 10.1038/s41392-024-02069-8

Verify or expand the search:

Other Meshalkin Research Institute of Pathology of Circulation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02861963.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing